Reports Q2 revenue $6,000 vs 8,000 last year. “We are pleased to have commenced enrollment in our IMPACT Phase 2b biopsy-driven trial of pemvidutide in NASH,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We believe our compelling Phase 1b data in subjects with nonalcoholic fatty liver disease demonstrating class-leading improvements in liver fat and markers of liver inflammation support the prospects of achieving robust rates of NASH resolution and fibrosis improvement in our IMPACT trial. We are also eager to report our 48-week data from the MOMENTUM Phase 2 obesity trial next quarter. We believe the pemvidutide data showing significant weight loss, combined with robust reductions in liver fat content, serum lipids and blood pressure without cardiovascular safety signals could offer a differentiated product profile that meaningfully impacts patients with obesity and NAFLD or dyslipidemia, and patients with NASH.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALT:
- Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
- ALT Upcoming Earnings Report: What to Expect?
- Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
- Altimmune announces initiation of Phase 2b IMPACT trial
- Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)